Stifel Initiates Coverage On Mentari Therapeutics with Buy Rating, Announces Price Target of $30
Benzinga Newsdesk 12 hours ago
Analyst RatingsNewsInitiationPrice Target
Stifel analyst Paul Matteis initiates coverage on Mentari Therapeutics (NASDAQ:MTRI) with a Buy rating and announces Price Target of $30.
Stifel analyst Paul Matteis initiates coverage on Mentari Therapeutics (NASDAQ:MTRI) with a Buy rating and announces Price Target of $30.